Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 6357.85
GNMSF's Cash to Debt is ranked higher than
77% of the 1244 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. GNMSF: 6357.85 )
GNMSF' s 10-Year Cash to Debt Range
Min: 10.54   Max: No Debt
Current: 6357.85

Equity to Asset 0.68
GNMSF's Equity to Asset is ranked higher than
74% of the 933 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. GNMSF: 0.68 )
GNMSF' s 10-Year Equity to Asset Range
Min: 0.21   Max: 0.68
Current: 0.68

0.21
0.68
F-Score: 7
Z-Score: 12.42
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) 30.25
GNMSF's Operating margin (%) is ranked higher than
95% of the 1022 Companies
in the Global Biotechnology industry.

( Industry Median: -78.59 vs. GNMSF: 30.25 )
GNMSF' s 10-Year Operating margin (%) Range
Min: -500.85   Max: 10760.13
Current: 30.25

-500.85
10760.13
Net-margin (%) 34.34
GNMSF's Net-margin (%) is ranked higher than
96% of the 1022 Companies
in the Global Biotechnology industry.

( Industry Median: -78.55 vs. GNMSF: 34.34 )
GNMSF' s 10-Year Net-margin (%) Range
Min: -10124.65   Max: 16.93
Current: 34.34

-10124.65
16.93
ROE (%) 22.06
GNMSF's ROE (%) is ranked higher than
96% of the 1141 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. GNMSF: 22.06 )
GNMSF' s 10-Year ROE (%) Range
Min: -112.03   Max: 21.55
Current: 22.06

-112.03
21.55
ROA (%) 12.31
GNMSF's ROA (%) is ranked higher than
95% of the 1248 Companies
in the Global Biotechnology industry.

( Industry Median: -27.84 vs. GNMSF: 12.31 )
GNMSF' s 10-Year ROA (%) Range
Min: -36.89   Max: 6.56
Current: 12.31

-36.89
6.56
ROC (Joel Greenblatt) (%) 1139.08
GNMSF's ROC (Joel Greenblatt) (%) is ranked higher than
99% of the 1220 Companies
in the Global Biotechnology industry.

( Industry Median: -415.02 vs. GNMSF: 1139.08 )
GNMSF' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -675.71   Max: 284.86
Current: 1139.08

-675.71
284.86
Revenue Growth (3Y)(%) -0.50
GNMSF's Revenue Growth (3Y)(%) is ranked higher than
78% of the 727 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. GNMSF: -0.50 )
GNMSF' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 331.5
Current: -0.5

0
331.5
» GNMSF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with GNMSF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 67.90
GNMSF's P/E(ttm) is ranked higher than
90% of the 1336 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. GNMSF: 67.90 )
GNMSF' s 10-Year P/E(ttm) Range
Min: 42.72   Max: 112.63
Current: 67.9

42.72
112.63
P/B 10.39
GNMSF's P/B is ranked higher than
65% of the 1336 Companies
in the Global Biotechnology industry.

( Industry Median: 6.37 vs. GNMSF: 10.39 )
GNMSF' s 10-Year P/B Range
Min: 1.63   Max: 25.05
Current: 10.39

1.63
25.05
P/S 22.47
GNMSF's P/S is ranked higher than
75% of the 1336 Companies
in the Global Biotechnology industry.

( Industry Median: 29.14 vs. GNMSF: 22.47 )
GNMSF' s 10-Year P/S Range
Min: 3.08   Max: 42.95
Current: 22.47

3.08
42.95
PFCF 694.71
GNMSF's PFCF is ranked higher than
90% of the 1336 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. GNMSF: 694.71 )
GNMSF' s 10-Year PFCF Range
Min: 3.77   Max: 694.71
Current: 694.71

3.77
694.71
EV-to-EBIT 67.99
GNMSF's EV-to-EBIT is ranked higher than
89% of the 1336 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. GNMSF: 67.99 )
GNMSF' s 10-Year EV-to-EBIT Range
Min: -390.4   Max: 1407.3
Current: 67.99

-390.4
1407.3
Current Ratio 3.79
GNMSF's Current Ratio is ranked higher than
70% of the 1237 Companies
in the Global Biotechnology industry.

( Industry Median: 4.71 vs. GNMSF: 3.79 )
GNMSF' s 10-Year Current Ratio Range
Min: 1.3   Max: 3.79
Current: 3.79

1.3
3.79
Quick Ratio 3.79
GNMSF's Quick Ratio is ranked higher than
70% of the 1237 Companies
in the Global Biotechnology industry.

( Industry Median: 4.53 vs. GNMSF: 3.79 )
GNMSF' s 10-Year Quick Ratio Range
Min: 1.3   Max: 3.79
Current: 3.79

1.3
3.79

Valuation & Return

vs
industry
vs
history
Price/Net Cash 11.54
GNMSF's Price/Net Cash is ranked higher than
81% of the 1336 Companies
in the Global Biotechnology industry.

( Industry Median: 52.60 vs. GNMSF: 11.54 )
GNMSF' s 10-Year Price/Net Cash Range
Min: 7.38   Max: 75.2
Current: 11.54

7.38
75.2
Price/Net Current Asset Value 11.54
GNMSF's Price/Net Current Asset Value is ranked higher than
80% of the 1336 Companies
in the Global Biotechnology industry.

( Industry Median: 31.80 vs. GNMSF: 11.54 )
GNMSF' s 10-Year Price/Net Current Asset Value Range
Min: 7.38   Max: 75.2
Current: 11.54

7.38
75.2
Price/Tangible Book 10.76
GNMSF's Price/Tangible Book is ranked higher than
70% of the 1336 Companies
in the Global Biotechnology industry.

( Industry Median: 9.60 vs. GNMSF: 10.76 )
GNMSF' s 10-Year Price/Tangible Book Range
Min: 1.62   Max: 22.67
Current: 10.76

1.62
22.67
Price/Median PS Value 2.80
GNMSF's Price/Median PS Value is ranked higher than
72% of the 1336 Companies
in the Global Biotechnology industry.

( Industry Median: 2.24 vs. GNMSF: 2.80 )
GNMSF' s 10-Year Price/Median PS Value Range
Min: 0.45   Max: 4.75
Current: 2.8

0.45
4.75
Price/Graham Number 5.74
GNMSF's Price/Graham Number is ranked higher than
90% of the 1336 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. GNMSF: 5.74 )
GNMSF' s 10-Year Price/Graham Number Range
Min: 4.08   Max: 10.78
Current: 5.74

4.08
10.78
Earnings Yield (Greenblatt) 1.50
GNMSF's Earnings Yield (Greenblatt) is ranked higher than
89% of the 1217 Companies
in the Global Biotechnology industry.

( Industry Median: -6.30 vs. GNMSF: 1.50 )
GNMSF' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 456.1
Current: 1.5

0.1
456.1

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:GEN.Denmark, 0MGB.UK,
Genmab A/S, incorporated on June 11, 1998, is a biotechnology company that utilizes antibody products. The Company's first marketed antibody, ofatumumab (Arzerra), was approved to treat chronic lymphocytic leukemia in patients who are refractory to fludarabine and alemtuzumab. Ofatumumab is marketed under a co-development and collaboration agreement with GlaxoSmithKline and has been launched in over two dozen countries. In addition to ofatumumab, it is building a pipeline of clinical and pre-clinical antibody products to treat cancer and for other diseases where there is an unmet medical need. Its product pipeline includes four antibodies in clinical development and over ten active pre-clinical programs.
» More Articles for GNMSF

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Genmab to Receive $3 Million Milestone Payment in DuoBody Platform Collaboration with Janssen Dec 12 2014
Genmab Announces Phase II Study of Daratumumab in Non-Hodgkin's Lymphomas Dec 04 2014
Genmab Announces Phase II Study of Daratumumab in Smoldering Multiple Myeloma Nov 24 2014
Genmab Announces New Phase III Combination Study of Daratumumab in Frontline Multiple Myeloma Nov 10 2014
Genmab Announces Daratumumab and Ofatumumab Data to Be Presented at American Society of Hematology... Nov 06 2014
Genmab Announces Additional Data from Phase III Study of Ofatumumab as Maintenance Therapy for... Nov 06 2014
Genmab Announces Financial Results for the First Nine Months of 2014 Nov 05 2014
Genmab Announces Conditional Transfer of Ofatumumab Agreement Nov 03 2014
Genmab Reaches USD 10 Million Milestone in Daratumumab Collaboration with Janssen Oct 23 2014
Third Quarter 2014 Net Sales Figures for Arzerra(r) Oct 22 2014
Genmab reports Q2 Arzerra net sales GBP 12.8M Jul 23 2014
Johnson & Johnson to Make $25M Milestone Payment to Genmab Jul 08 2014
Glaxo, Genmab report phase III ofatumumab study did not meet primary endpoint May 19 2014
Genmab says Janssen to start new Phase III study of daratumumab May 01 2014
Can Genmab (GNMSF) Run Higher on Strong Earnings Estimate Revisions? Jan 02 2014
Why Genmab A/S (GNMSF) Stock Might be a Great Pick Dec 31 2013
Senesco: Near-Term Catalyst Could Double Shareprice Dec 27 2013

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK